Anson Funds Management LP Has $2.42 Million Stock Holdings in NRx Pharmaceuticals, Inc. $NRXP

Key Points

• Anson Funds Management LP increased its holdings in NRx Pharmaceuticals by 535.1%, acquiring over 993,401 shares in the first quarter, bringing its total to approximately $2.42 million.
• NRx Pharmaceuticals reported disappointing earnings, with an EPS of ($0.98) for the latest quarter, missing analysts' estimates by ($0.67).
• Analysts have mixed views on NRx Pharmaceuticals, with a consensus average rating of "Buy" and an average target price of $28.50.

Anson Funds Management LP boosted its position in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Free Report) by 535.1% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,179,061 shares of the company's stock after buying an additional 993,401 shares during the period. Anson Funds Management LP owned approximately 6.85% of NRx Pharmaceuticals worth $2,417,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Sassicaia Capital Advisers LLC acquired a new position in shares of NRx Pharmaceuticals during the fourth quarter worth approximately $33,000. Squarepoint Ops LLC bought a new stake in NRx Pharmaceuticals during the 4th quarter valued at $56,000. Millennium Management LLC acquired a new position in NRx Pharmaceuticals during the fourth quarter worth $61,000. Finally, AdvisorShares Investments LLC lifted its stake in shares of NRx Pharmaceuticals by 138.5% in the fourth quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company's stock valued at $683,000 after buying an additional 180,229 shares in the last quarter. Institutional investors and hedge funds own 4.27% of the company's stock.

NRx Pharmaceuticals Price Performance

NASDAQ NRXP opened at $2.64 on Friday. The business's fifty day moving average is $2.98 and its 200-day moving average is $2.56. The stock has a market capitalization of $52.30 million, a price-to-earnings ratio of -1.18 and a beta of 1.59. NRx Pharmaceuticals, Inc. has a one year low of $1.10 and a one year high of $6.01.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last released its earnings results on Monday, August 18th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.67). Research analysts expect that NRx Pharmaceuticals, Inc. will post -1.75 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on NRXP shares. D. Boral Capital restated a "buy" rating and issued a $31.00 target price on shares of NRx Pharmaceuticals in a report on Tuesday, August 19th. Ascendiant Capital Markets increased their price objective on NRx Pharmaceuticals from $45.00 to $46.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Finally, Wall Street Zen raised NRx Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. One research analyst has rated the stock with a Strong Buy rating and four have given a Buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $28.50.

NRx Pharmaceuticals Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.

Want to see what other hedge funds are holding NRXP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.